Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.32 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240093 | 0.88 | KMT2A (0.39) | GRM2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL240827 | 0.86 | FFAR4 (0.33) | MAPTMEN1KMT2ASMN1; SMN2FFAR4 | |
| SCHEMBL241269 | 0.85 | ALDH1A1 (0.37) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL240260 | 0.85 | ALDH1A1 (0.37) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL237500 | 0.84 | MAPT (0.39) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL241307 | 0.83 | FFAR4 (0.32) | MAPTMEN1KMT2ASMN1; SMN2FFAR4 | |
| SCHEMBL240800 | 0.83 | HTT (0.43) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL240369 | 0.83 | SIGMAR1 (0.35) | MAPTMEN1KMT2A | |
| SCHEMBL240305 | 0.83 | ALDH1A1 (0.39) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL238468 | 0.83 | ALDH1A1 (0.39) | MAPTMEN1KMT2ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20150087618-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | GRM2 4755/4885MAPT 2833/4885MEN1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.